Looking for Partnerships to Combat COVID-19

Updated: May 15

KLUS Pharma is currently seeking co-development partnerships to conduct clinical trials on COVID-19 patients in countries and regions most affected by the pandemic. Our investigational product (ACV200-17) is an inhaled peptide intended for prophylactic treatment of COVID-19 infection

ACE2 protein is widely expressed in the human respiratory tract. Coronavirus SARS-CoV-2 infects human cells by binding to ACE2 on the cell surface via interaction with viral S protein. Results from both nonclinical studies have demonstrated that ACV200-17 could be a promising drug to prevent the further spread of COVID-19.

  • ACV200-17 blocks interactions between ACE2 and the viral S protein in vitro.

  • Confirmed MOA and demonstrated efficacy in animal studies.

  • Safety studies showed good tolerance in mouse and monkey models when given as single intravenous administration and inhalation.

  • Demonstrated safety in healthy volunteers when given as single and repeated inhalation.

  • The product has an established GMP production capacity.

KLUS Pharma is actively seeking collaboration opportunities to accelerate the development and commercialization of ACV200-17 in the US and EU, in order to help combat the spread of the current COVID-19 pandemic.

KLUS Pharma Inc.

Cranbury, New Jersey, US

©2020 by KLUS Pharma Inc.